Core Viewpoint - The announcement of an exclusive cooperation agreement between Zhixiang Jintai and Kangzhe Pharmaceutical is expected to significantly enhance the company's market position and financial performance through the commercialization of two monoclonal antibodies [1][2]. Group 1: Agreement Details - Zhixiang Jintai signed an exclusive cooperation agreement with Kangzhe Pharmaceutical and its subsidiaries, which includes a total payment of up to 260 million RMB, consisting of upfront and milestone payments [1]. - The agreement grants Zhixiang Jintai exclusive commercialization rights for Weikang Duta monoclonal injection and Sileweimi monoclonal injection in mainland China and the Asia-Pacific region [1]. Group 2: Market Impact - Following the announcement, Zhixiang Jintai's stock price rose by 1.41% to 33.79 RMB per share, with a trading volume of 129 million RMB, reflecting positive market sentiment [2]. - Despite a slight decline of 0.18% in the stock price over the past seven trading days, the announcement has boosted investor confidence and increased attention on the company [2]. Group 3: Strategic Outlook - The cooperation is seen as a strategic move to enhance Zhixiang Jintai's market competitiveness and position within the biopharmaceutical industry, responding proactively to future market demands [1][4]. - The company aims to deepen resource integration with key partners, enhance R&D capabilities, and optimize product structure to drive overall transformation and long-term growth [4].

Group 1 - Shengxin Lithium Energy plans to acquire 21% stake in Qicheng Mining for 1.456 billion yuan, increasing its ownership to 70% [4] - Tianpu Co. has seen its stock rise 279.73% over 14 consecutive trading days, but the acquirer Zhonghao Xinying has no asset injection plan [5] - Hangdian Co. reports losses in its optical communication business while its copper foil business is still in the early stages [6][7] Group 2 - Tianchuang Fashion is launching a shareholder reward activity, offering 70% discount coupons to shareholders [8] - Beiliang Co. is collaborating with Tonghuashun to host a "Shareholder Festival" for past investors [9] - Xinxiang Chemical Fiber will undergo a 90-day orderly shutdown for equipment upgrades, affecting 31,200 tons/year capacity and expected revenue loss of approximately 185 million yuan [10] Group 3 - Bozhong Precision plans to transfer 18.29% stake in Suzhou Linghou Robotics for 64 million yuan [11] - Tiancai Self-Control has received a project confirmation from a leading domestic new energy vehicle company for seat assembly, expected to start production in June 2026 [12] - Huazi Industrial's subsidiary plans to sell dairy farm assets for 38.5 million yuan, impacting current profits by approximately 11.7 million yuan [13] Group 4 - Oriental Pearl plans to invest in a special fund to acquire equity in Chaoyuan Digital Technology, committing 244 million yuan [14] - Daotong Technology intends to transfer 46% stake in Shenzhen Saifang Technology for 109 million yuan, focusing on core business development [15] - Lepu Medical has signed a strategic cooperation agreement with Hanhai Information to enhance online sales channels for its aesthetic medicine segment [16] Group 5 - Dingxin Communications clarifies that its technology authorization from Pingtouge is unrelated to AI chip development [17] - Changchuan Technology expects a net profit increase of 131.39% to 145.38% year-on-year for the first three quarters of 2025, driven by strong semiconductor demand [18] Group 6 - Guangdong Construction has won a construction contract worth 1.924 billion yuan for a property reconstruction project [19] - Youxunda is expected to win a procurement project from the State Grid worth approximately 107 million yuan, representing 10.55% of its 2024 revenue [20] - Samsung Medical anticipates winning procurement projects from the State Grid totaling about 193 million yuan [21] Group 7 - Baiyun Electric is a candidate for multiple procurement projects from the State Grid, with a total expected amount of 162 million yuan [22] - *ST Weihe is a candidate for a 141 million yuan engineering project [23] - Plad has signed a strategic cooperation agreement with a well-known international power tool brand for over 700 million yuan in purchases over five years [25] Group 8 - Lanhua Kecai has signed a strategic cooperation agreement with Panhu Power for joint development of axial flux motors [26] - Zhixiang Jintai has entered into commercialization agreements for two monoclonal antibody injections, gaining exclusive rights in various regions [27] - Honggong Technology plans to invest up to 450 million yuan in a project with the Changsha Economic Development Zone [28] Group 9 - Zhejiang Medicine's major shareholder plans to reduce its stake by up to 1% [29] - Su Yan Jingshen's directors plan to collectively increase their holdings by 1.9 to 2.66 million yuan [30] - Zhongdian Electric's shareholder intends to reduce its stake by up to 3% [32] Group 10 - Sanfu New Science plans to repurchase shares worth 10 to 15 million yuan for employee stock incentives [41] - Guiyan Platinum plans to raise up to 1.291 billion yuan for technology innovation and industry upgrades [42] - Zhongjing Electronics plans to raise up to 700 million yuan, with the controlling shareholder participating in the subscription [43]

Core Viewpoint - 康哲药业 has signed exclusive collaboration agreements with 重庆智翔金泰 for the commercialization of two monoclonal antibody products, 唯康度塔单抗 (GR2001) and 斯乐韦米单抗 (GR1801), targeting passive immunity for tetanus and rabies respectively, with exclusive rights in mainland China and other regions [1][2]. Group 1: Product Details - 唯康度塔单抗 is a recombinant humanized monoclonal antibody targeting the C-terminal of Tetanus Neurotoxin (TeNT), which blocks its entry into neurons, providing passive immunity [2]. - 斯乐韦米单抗 is a recombinant fully human bispecific antibody targeting the glycoprotein of Rabies Virus (RABV), preventing the virus from infecting neurons before the active immunity from rabies vaccine takes effect [2]. Group 2: Market Potential and Strategic Impact - The passive immunity market for tetanus and rabies is significant, with existing products having limitations in safety and accessibility [3]. - 唯康度塔单抗 offers better safety and efficacy compared to human tetanus immunoglobulin (HTIG), providing rapid and long-lasting protection [3]. - 斯乐韦米单抗 is the first globally to target specific epitopes of the rabies virus glycoprotein, aligning with WHO development recommendations, and is expected to be produced in a standardized and cost-effective manner [3]. - If approved, these products will provide new treatment options for patients in China and are anticipated to positively impact the company's performance through synergy with existing products [3].

Core Viewpoint - The company has signed exclusive collaboration agreements for two monoclonal antibody products, GR2001 and GR1801, which target passive immunity for tetanus and rabies, respectively, with a focus on commercialization in mainland China and the Asia-Pacific region, as well as the Middle East and North Africa [1][2]. Group 1: Product Details - GR2001 is a recombinant humanized monoclonal antibody targeting the C-terminal of Tetanus Neurotoxin (TeNT), providing passive immunity by blocking TeNT from entering neuronal cells [2]. - GR1801 is a recombinant fully human bispecific antibody targeting the glycoprotein of the rabies virus, preventing the virus from infecting neurons before the active immunity from rabies vaccination takes effect [2]. Group 2: Market Potential and Strategic Positioning - The passive immunity market for tetanus and rabies is significant, with existing products having limitations in safety and accessibility [3]. - GR2001 offers better safety and efficacy compared to human tetanus immunoglobulin (HTIG), providing rapid and long-lasting protection for patients [3]. - GR1801 is the first globally to target specific epitopes of the rabies virus glycoprotein, aligning with WHO development recommendations, and is designed for large-scale standardized production [3]. - If approved, both products are expected to provide new treatment options for patients in China and positively impact the company's performance through synergy with existing products [3].

智翔金泰表示，根据协议，公司将获得首付款、里程碑付款约5.1亿元，并获得其商业化推广等服务， 西藏康哲将获得上述两款产品在中国大陆的独家商业化权，RXILIENT将获得上述两款产品除中国大陆 之外的亚太地区及中东、北非的独家许可权。 北京商报讯（记者 丁宁）9月22日晚间，智翔金泰（688443）发布公告称，公司与康哲药业控股有限公 司之附属公司西藏康哲药业发展有限公司（以下简称"西藏康哲"）和RXILIENT MEDICAL PTE. LTD.就 唯康度塔单抗注射液（GR2001注射液）以及斯乐韦米单抗注射液（GR1801注射液）分别签订独家合作 协议。 ...

格隆汇9月22日丨智翔金泰(688443.SH)公告称，与康哲药业附属公司西藏康哲和RXILIENT就唯康度塔 单抗注射液(GR2001注射液)以及斯乐韦米单抗注射液(GR1801注射液)分别签订独家合作协议。西藏康 哲将获得两款产品在中国大陆的独家商业化权，RXILIENT将获得除中国大陆之外的亚太地区及中东、 北非的独家许可权。智翔金泰将获得首付款、里程碑付款约5.1亿元人民币等权益。该合作对公司业绩 提升及长期发展有积极影响，但存在药品注册进程及商业化不确定性风险。 ...

康哲药业公告，公司附属公司与中国生物制药企业智翔金泰签订合作协议，获得了唯康度塔单抗注射液 和斯乐韦米单抗注射液在中国大陆的独家商业化权，以及亚太地区和中东、北非的独家许可权。唯康度 塔单抗注射液用于破伤风治疗，斯乐韦米单抗注射液用于狂犬病治疗。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 自願性及業務進展公告 就1類創新型治療用生物製品 重組人源化抗破傷風毒素單克隆抗體唯康度塔單抗注射液 及重組全人源抗狂犬病病毒雙特異性抗體斯樂韋米單抗注射液 簽訂合作協議 China Medical System Holdings Limited（「本公司」，連同其附屬公司統稱為「本 集團」）欣然宣佈，於二零二五年九月二十二日，本集團通過本公司附屬公司與重慶智 翔金泰生物製藥股份有限公司（「智翔金泰」）就用於破傷風的被動免疫適應症的1類 治療用生物製品唯康度塔單抗（GR2001）注射液（「唯康度塔單抗注射液」）及用於疑 似狂犬病病毒暴露後的被動免疫適應症的1類治療用生物製品斯樂韋米單抗（GR1801） 注射液（「斯樂韋米單抗注射液」）分別簽訂獨家合作協議（「協議」）。 根據協議，本集團獲得了唯康度塔單抗注射液及斯樂韋米單抗注射液在中國大陸的獨家 商業化權與除中國大陸之外的亞太地區及中東、北非的獨家許可權。合作 ...

根据《GR1801注射液独家合作协议》，西藏康哲将获得斯乐韦米单抗注射液在中国大陆的独家商业化 权，RXILIENT将获得斯乐韦米单抗注射液除中国大陆之外的亚太地区及中东、北非的独家许可权，智 翔金泰将获得首付款、里程碑付款至高约2.5亿元人民币、中国大陆区域销售收入以及除中国大陆之外 的亚太地区及中东、北非区域基于净销售额调整的供货收入。同时，公司将根据协议约定就中国大陆区 域的销售收入向西藏康哲支付推广服务费。 智翔金泰(688443.SH)发布公告，近日，公司与康哲药业控股有限公司(简称"康哲药业")之附属公司西藏 康哲药业发展有限公司(简称"西藏康哲")和RXILIENT MEDICAL PTE.LTD.(简称"RXILIENT")就唯康度 塔单抗注射液(GR2001注射液)以及斯乐韦米单抗注射液(GR1801注射液)分别签订独家合作协议。根据 协议，公司将获得首付款、里程碑付款并获得其商业化推广等服务，西藏康哲将获得上述两款产品在中 国大陆的独家商业化权，RXILIENT将获得上述两款产品除中国大陆之外的亚太地区及中东、北非的独 家许可权。 根据《GR2001注射液独家合作协议》，西藏康哲将获得唯康 ...

根据《GR1801 注射液独家合作协议》，西藏康哲将获得斯乐韦米单抗注射液在中国大陆的独家商业化 权，RXILIENT 将获得斯乐韦米单抗注射液除中国大陆之外的亚太地区及中东、北非的独家许可权，智 翔金泰将获得首付款、里程碑付款至高约2.5亿元人民币、中国大陆区域销售收入以及除中国大陆之外 的亚太地区及中东、北非区域基于净销售额调整的供货收入。同时，公司将根据协议约定就中国大陆区 域的销售收入向西藏康哲支付推广服务费。 智通财经APP讯，智翔金泰(688443.SH)发布公告，近日，公司与康哲药业控股有限公司(简称"康哲药 业")之附属公司西藏康哲药业发展有限公司(简称"西藏康哲")和 RXILIENT MEDICAL PTE. LTD.(简 称"RXILIENT")就唯康度塔单抗注射液(GR2001 注射液)以及斯乐韦米单抗注射液(GR1801 注射液)分别 签订独家合作协议。根据协议，公司将获得首付款、里程碑付款并获得其商业化推广等服务，西藏康哲 将获得上述两款产品在中国大陆的独家商业化权，RXILIENT 将获得上述两款产品除中国大陆之外的亚 太地区及中东、北非的独家许可权。 根据《GR2001 注射液 ...